KRP-M223 – Talk Bio

Actionable Insights Powered by AI

Novartis Licenses Kyorin’s Preclinical Chronic Hives Drug for $55M Upfront

2 months ago talkbio0Tagged chronic, Dosage Forms, KRP, KRP-M223, Kyorin, MRGPRX2 gene, Novartis

Novartis, Kyorin Pharmaceutical, KRP-M223, chronic spontaneous urticaria, licensing deal, MRGPRX2 antagonist

Novartis Secures Global Rights to Kyorin’s KRP-M223 for Allergic and Inflammatory Diseases

2 months ago talkbio0Tagged Antagonist muscle action, chronic, Dosage Forms, Dupixent, KRP, KRP-M223, Kyorin, licensing agreement, MRGPRX2 gene, Novartis

Novartis, Kyorin Pharmaceutical, KRP-M223, MRGPRX2 antagonist, chronic spontaneous urticaria, Dupixent, licensing agreement